Protalex, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Protalex, Inc. - overview
Established
1999
Location
Florham Park, NJ-New Jersey, US
Primary Industry
Biotechnology
About
Founded in 1999, Protalex is focused on developing innovative therapeutics for autoimmune diseases, leveraging advanced technology to create effective treatments that improve patient outcomes. Protalex specializes in biopharmaceutical development aimed at addressing autoimmune diseases. The company is headquartered in New Hope, US. Founded by John Doherty, Protalex has secured funding through a PIPE round, raising USD 15.
20 mn from investors including Bluebee Software, Emerging Technology Partners, and Signal Peak Ventures. This latest funding round marks the total amount raised by the company. Protalex develops therapeutic solutions targeting autoimmune diseases, emphasizing innovation in treatment methodologies. Their research programs focus on creating biologic drugs that can modify the immune response effectively, aimed at providing durable outcomes for patients suffering from chronic conditions.
This commitment to research and development positions Protalex at the forefront of therapeutic advancements in the biopharmaceutical sector. In 2018, Protalex reported no revenue, with an EBITDA of USD -4,348,492. The company's focus on strategic development activities means that revenue generation is expected to align with the successful advancement of their drug candidates and market entry. Protalex aims to expand its product pipeline with upcoming therapies designed for autoimmune diseases, although specific launch dates remain undisclosed.
The company is also looking to penetrate new geographic markets, particularly in North America, to reach broader patient populations. Recent funding from the PIPE round will support these initiatives, allowing Protalex to enhance its research capabilities and facilitate the development of new therapeutics.
Current Investors
Pontifax Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.protalex.com
Total Amount Raised
Subscriber access only
Protalex, Inc. - timeline of key events
Protalex, Inc. - financials
| Fiscal Year Ended | May 31, 2009 | May 31, 2010 | May 31, 2011 | May 31, 2012 | May 31, 2013 | May 31, 2014 | May 31, 2015 | May 31, 2016 | May 31, 2017 | May 31, 2018 | May 31, 2019 | May 31, 2020 | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (4,528,195.483) | (1,785,373.132) | (1,213,164.628) | (1,615,898.804) | (3,582,679.391) | (7,170,912.655) | (7,137,694.036) | (6,015,676.548) | (3,134,755.274) | (3,241,401.749) | - | - | - | - | - | - | - | - |
| Operating Income (USD) | (4,559,017.306) | (1,866,912.915) | (1,672,863.911) | (2,203,945.926) | (3,583,329.709) | (7,171,544.972) | (7,138,338.436) | (6,016,359.834) | (3,135,553.605) | (3,298,162.35) | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (4,474,951.881) | (1,926,373.612) | (2,128,834.75) | (2,796,684.619) | (4,004,066.148) | (7,347,426.008) | (7,340,987.36) | (6,307,298.282) | (3,571,920.411) | (3,754,012.284) | - | - | - | - | - | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Protalex, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Protalex, Inc. | - | ||||||||
| Buyout | Completed | Protalex, Inc. | - |
Displaying 1 - 2 of 2
Protalex, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.